Jazz Pharmaceuticals plc (JAZZ) is a global biopharmaceutical company that produces life-changing medicines for people suffering from complicated and serious health problems. The company was founded in 2003 and is headquartered in Dublin, Ireland. Jazz Pharmaceuticals is primarily involved in the development and commercialization of pharmaceutical products to address unmet medical needs in neurology and oncology.
Well-known for their dedication to enhancing patients’ lives, Jazz Pharmaceuticals aims to identify, develop, and market products that have the potential to address overlooked and underserved medical needs. Its passion for patients and high therapeutic focus have guided the company to bring a variety of important medicines to market.
The company's well-rounded portfolio includes sleep medicine like Xyrem, (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. They also offer Erwinaze, an oncology drug for the treatment of Acute Lymphoblastic Leukemia in patients with hypersensitivity to E. coli-derived asparaginase, and Vyxeos, a drug for newly diagnosed therapy-related acute myeloid leukemia. Jazz Pharmaceuticals' continuous engagement in the healthcare field has resulted in the development of effective treatment options that have transformed lives globally.
Jazz Pharmaceuticals is also known for its progressive and unique corporate culture that emphasizes teamwork, integrity, and innovation. This has led to numerous advancements and medical breakthroughs, which make the company a standout within the biopharmaceutical industry.
In addition, Jazz Pharmaceuticals has demonstrated a profound commitment to developing healthcare solutions globally. Its widespread presence includes manufacturing and commercializing efforts in markets such as North America, Europe, and rest of the world. Over the years, Jazz Pharmaceuticals has experienced significant growth and is looking forward to more achievements in the future as it continues to strive for the next discovery that could revolutionize healthcare. Its mission is to bring hope and improve the quality of life of patients by advancing and maximizing the impact of its important and innovative medicines.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Bruce C. Cozadd, a Board Member at Jazz Pharmaceuticals (NASDAQ: JAZZ), exercised stock options for 86,500 shares valued at $9,455,315, as disclosed in a recent SEC filing. The article also provides a company overview of Jazz Pharmaceuticals, focusing on its financial health, including revenue growth, gross margin, EPS, debt management, and various valuation ratios. It emphasizes the importance of insider transactions as part of a comprehensive investment analysis.
Patricia Carr, SVP and Chief Accounting Officer at Jazz Pharmaceuticals plc, executed 1,250 non-qualified stock options at $140.03 per share on November 4, 2026. On the same day, she sold 1,250 ordinary shares at $231.37 each and an additional 163 shares at $231.27. Following these transactions, Carr directly held 6,512 ordinary shares and retained 3,000 non-qualified stock options.
Jazz Pharmaceuticals (JAZZ) reported a record $1.24 billion in Q3 revenue, driven by strong sales in its sleep and oncology portfolios, leading to a raised full-year guidance for 2026. Despite a GAAP net loss of $483 million, largely due to a $754 million acquired in-process R&D charge from the Actio Biosciences acquisition, the underlying commercial business remains robust. The company's diversified portfolio and growth catalysts are seen as positive, though high debt and pipeline execution risks remain key considerations for investors.
This article examines three biotech stocks – Jazz Pharmaceuticals, Arrowhead Pharmaceuticals, and Trulieve Cannabis – that are being closely watched by investors. It highlights how these companies, despite the high-risk nature of the biotech sector, offer strong financial positions and unique value propositions, from oncology and CNS therapies to RNAi-based medicines and medical cannabis products. The analysis delves into their current operations, future growth potential, and specific factors that could influence their long-term earnings and cash generation.
Jazz Pharmaceuticals (JAZZ) is drawing attention after updated Phase 3 HERIZON GEA 01 data showed Ziihera-based regimens significantly cut mortality risk and achieved the longest reported median overall survival in its treatment setting. Despite a recent share price pullback, the company's long-term returns remain strong, and it currently screens as undervalued with an implied fair value of $294.27 against a last close of $206.78. The company's narrative is shifting towards an oncology-centric and cash-flow-durability story, with Ziihera as the main growth driver.
Jazz Pharmaceuticals' financial performance is improving, largely driven by its expanding oncology business, which saw a nearly 32% year-over-year revenue increase in the second quarter. The company is actively diversifying its portfolio with promising new oncology drugs like Ziihera and Modeyso, reducing reliance on its established narcolepsy treatments. Despite competitive threats to its Xywav product, Jazz Pharmaceuticals appears to be an attractive investment for long-term holders due to its strong oncology pipeline and favorable valuation compared to the healthcare industry average.